Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant Capecitabine in Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck.

JAMA dermatology·2026
Same author

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with Triple Negative Breast Cancer in Both the Early and Metastatic Setting 2025.

Current oncology (Toronto, Ont.)·2026
Same author

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update).

Current oncology (Toronto, Ont.)·2026
Same author

Practical management of antineoplastic-induced nausea and vomiting from antibody-drug conjugates: Insights from a Canadian expert panel.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026
Same author

Predicting treatment intolerance in operable head and neck cancer using the modified head and neck surgery risk index.

Oral oncology·2026
Same author

Correction to: A Canadian real‑world, multi‑center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2‑negative advanced breast cancer.

Breast cancer research and treatment·2026

Related Experiment Video

Updated: Dec 25, 2025

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.9K

Post-mortem tissue donation programs as platforms to accelerate cancer research.

Matthew Dankner1, Badia Issa-Chergui2,3, Nathaniel Bouganim4,3

  • 1Goodman Cancer Research Centre, McGill University, Quebec, Canada.

The Journal of Pathology. Clinical Research
|March 22, 2020
PubMed
Summary

Post-mortem tissue donation offers a vital resource for studying treatment-resistant and inoperable metastases in cancer patients. This approach aids in understanding metastatic dissemination and improving advanced cancer care.

Keywords:
cancer researchpost-mortem tissue donationrapid autopsyrapid tissue donation

More Related Videos

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
08:46

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG

Published on: March 7, 2017

17.4K
Study of Experimental Organ Donation Models for Lung Transplantation
08:56

Study of Experimental Organ Donation Models for Lung Transplantation

Published on: March 15, 2024

1.9K

Related Experiment Videos

Last Updated: Dec 25, 2025

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.9K
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
08:46

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG

Published on: March 7, 2017

17.4K
Study of Experimental Organ Donation Models for Lung Transplantation
08:56

Study of Experimental Organ Donation Models for Lung Transplantation

Published on: March 15, 2024

1.9K

Area of Science:

  • Oncology
  • Pathology
  • Translational Medicine

Background:

  • Cancer treatments have improved survival, but treatment-resistant and inoperable metastases remain a significant challenge.
  • Studying these complex metastatic lesions requires access to diverse tissue specimens, which are often unavailable.
  • Patients with advanced or rapidly progressing cancer are typically not surgical candidates, limiting direct research on their disease.

Purpose of the Study:

  • To highlight the critical need for multi-site metastatic tissue specimens in cancer research.
  • To discuss the growing importance and implementation of post-mortem tissue donation programs in oncology.
  • To propose future research directions utilizing post-mortem tissues to advance clinical management of advanced cancers.

Main Methods:

  • Review of current literature on cancer treatment outcomes and metastatic disease.
  • Analysis of the utility and feasibility of post-mortem tissue donation for cancer research.
  • Exploration of existing studies that have successfully utilized post-mortem tissue resources.
  • Discussion of ethical considerations and public attitudes towards post-mortem tissue donation.

Main Results:

  • Post-mortem tissue donation provides a unique and often irreplaceable resource for studying metastatic cancer.
  • These programs address the critical gap in obtaining tissue from multiple metastatic sites within individual patients.
  • Existing research demonstrates the value of post-mortem tissues in advancing the understanding of cancer progression and therapeutic resistance.

Conclusions:

  • Post-mortem tissue donation is an essential strategy to overcome limitations in studying advanced, treatment-resistant cancers.
  • Further development and utilization of these programs will accelerate discoveries in metastatic dissemination and inoperable tumor biology.
  • This research approach holds significant promise for improving therapeutic strategies and clinical outcomes for advanced cancer patients.